Key Takeaways & Executive Findings
- •• Drug repurposing offers a cost-effective and time-efficient alternative to traditional drug development, leveraging existing safety data. • Regulatory pathways such as the 505(b)(2) application and similar frameworks in other regions are critical enablers for drug repurposing. • Computational methods and real-world data are increasingly used to identify repurposing candidates and support regulatory submissions. • Harmonization of regulatory standards and data sharing can accelerate the translation of repurposing opportunities into clinical practice.
Abstract
Drug repurposing, the process of identifying new therapeutic uses for approved or investigational drugs, has emerged as a promising strategy to accelerate drug development and reduce costs. This paper provides a comprehensive review of the current landscape of drug repurposing within the context of the evolving drug regulatory framework. We discuss the scientific rationale, including the use of computational approaches and real-world data, and examine regulatory pathways that facilitate repurposing, such as the 505(b)(2) application in the United States and similar mechanisms in other jurisdictions. The paper highlights challenges, including intellectual property issues, data exclusivity, and the need for robust clinical evidence. Through case studies, we illustrate successful repurposing efforts and analyze the impact on drug development timelines and patient access. Our findings suggest that a harmonized regulatory approach, coupled with advanced data analytics, can significantly enhance the efficiency of drug repurposing. We propose recommendations for stakeholders, including regulators, industry, and academia, to foster innovation while ensuring safety and efficacy. This review aims to provide a foundational understanding of drug repurposing and its regulatory implications, serving as a resource for researchers and policymakers.
1. Introduction
Drug repurposing, also known as drug repositioning, has gained significant attention as a strategy to address the high costs and long timelines associated with traditional drug development. By identifying new indications for existing drugs, repurposing can bypass early-phase safety studies, thereby reducing development time and financial risk. The approach has been particularly valuable in areas of unmet medical need, such as rare diseases and emerging infectious diseases, where conventional development may be economically unviable.
However, the successful implementation of drug repurposing is contingent upon a supportive regulatory environment. Regulatory agencies have established pathways to facilitate the approval of repurposed drugs, yet challenges remain, including intellectual property barriers and the need for adequate clinical evidence. This paper reviews the current state of drug repurposing, with a focus on regulatory frameworks, and discusses the opportunities and obstacles that shape its future.
Loading authentic research manuscript (Pages 1–5)...
ZHANG Wei, LI Ming (2025). Drug Repurposing and Its Application in the Context of the Current Drug Regulatory Framework. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_257
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is drug repurposing?
Drug repurposing, also known as drug repositioning, is the process of identifying new therapeutic uses for existing approved or investigational drugs. This strategy can accelerate drug development by leveraging existing safety and pharmacokinetic data.
What are the main regulatory pathways for drug repurposing?
In the United States, the 505(b)(2) application is a key pathway, allowing reliance on data not developed by the applicant. Other regions have similar mechanisms, such as the European Medicines Agency's Article 10(3) for biosimilars and hybrid applications.
How does real-world data contribute to drug repurposing?
Real-world data, including electronic health records and claims data, can provide evidence of drug effectiveness and safety in broader populations, supporting repurposing hypotheses and regulatory submissions.
What are the main challenges in drug repurposing?
Challenges include intellectual property issues, data exclusivity, regulatory uncertainty, and the need for robust clinical evidence to demonstrate efficacy for the new indication.
Can drug repurposing help in rare diseases?
Yes, drug repurposing is particularly valuable for rare diseases, where the patient population is small and traditional development may be economically unfeasible. It can provide faster access to treatments for patients with unmet needs.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.